We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
-19.57%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$355M
AUM Growth
-$300M
(-46%)
Cap. Flow
-$20.6M
Cap. Flow
% of AUM
-5.79%
Top 10 Holdings %
Top 10 Hldgs %
98.85%
Holding
12
New
1
Increased
1
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$10.1M |
| 2 |
VINCW
Vincerx Pharma, Inc. Warrant
VINCW
|
+$2.77M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rocket Pharmaceuticals
RCKT
|
+$23.8M |
| 2 |
VINCU
Vincerx Pharma, Inc. Unit
VINCU
|
+$9.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Rocket Pharmaceuticals
RCKT
$355M
| $112M | 31.61% |
2,531,800
-433,685
| -15% | -$23.8M |
|
2
AnaptysBio
ANAB
$1.59B
| $56.6M | 15.94% |
2,628,678
| – | – |
|
3
Aptevo Therapeutics
APVO
$5.25M
| $53.7M | 15.11% |
3
| – | – |
|
|
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $53.1M | 14.93% |
15,514,566
| – | – |
|
|
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $39.9M | 11.22% |
9,405,490
| – | – |
|
|
VINC
6
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $9.65M | 2.72% |
+25,000
| New | +$10.1M |
|
7
Coherus Oncology
CHRS
$225M
| $9.5M | 2.67% |
650,000
| – | – |
|
8
Relmada Therapeutics
RLMD
$546M
| $7.04M | 1.98% |
200,000
| – | – |
|
9
Tango Therapeutics
TNGX
$4.35B
| $5.21M | 1.47% |
468,750
| – | – |
|
10
Equillium
EQ
$156M
| $4.29M | 1.21% |
600,000
| – | – |
|
|
VINCW
11
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
| $4.1M | 1.15% |
1,014,368
+684,163
| +207% | +$2.77M |
|
|
VINCU
12
DELISTED
Vincerx Pharma, Inc. Unit
VINCU
| – | – |
-500,000
| Closed | -$9.63M |
|
Similar funds
HA
SGAM
CCA
FWTB
NIM
RMCM
FC
SC
Tang Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Tang Capital Management held 12 positions worth $355M, down 46% from $655M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Tang Capital Management withdrew a net $20.6M in Q1 2021, closing 1 position and reducing 1 holding. Its most notable exit was Vincerx Pharma, Inc. Unit, an estimated $9.63M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.
Against the trend, Tang Capital Management opened a new position in Vincerx Pharma, Inc. Common Stock worth $9.65M.
- Tang Capital Management's largest Q1 2021 buy was Vincerx Pharma, Inc. Common Stock: 25,000 shares worth $9.65M.
- Tang Capital Management added most to Vincerx Pharma, Inc. Warrant in Q1 2021, an estimated $2.77M increase.
- Tang Capital Management's biggest Q1 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $23.8M.
- Tang Capital Management fully exited Vincerx Pharma, Inc. Unit in Q1 2021, selling an estimated $9.63M.
- Tang Capital Management's ten largest holdings make up 99% of its $355M portfolio in Q1 2021.
- Tang Capital Management opened 1 new position and closed 1 in Q1 2021.
- Tang Capital Management's portfolio value fell 46% quarter-over-quarter to $355M.
Based on Tang Capital Management's 13F filing for Q1 2021, filed 17 May 2021.